Investor Alert - Cybin: Changing the Mental Healthcare Experience

January 17, 2022

On a mission to revolutionize mental healthcare

Cybin is a biotech company in the psychedelic therapeutic sector. Their team is focused on the development of mental healthcare treatment with a single-minded goal to dramatically improve patient outcomes versus currently available pharmacotherapies.

Their work includes the development of new drug molecules, with a focus on optimizing treatment outcomes through innovative drug delivery systems, concurrent therapy regimens, and technology-driven patient analytics.

For more information on Cybin Inc. (NEO: CYBN, NYSE AMERICAN: CYBN) please click the request investor info button.

You might also like

Healthcare
Medicus Pharma: Treatment with Non-Invasive Solutions

Medicus Pharma is transforming skin cancer care with its innovative, non-invasive chemotherapy delivery system, providing a safer and more effective alternative to traditional surgery.

Healthcare
Lexaria Bioscience: Revolutionizing GLP-1 Drug Delivery with Patented Oral Platform

Lexaria Bioscience is setting new standards in drug delivery with its patented DehydraTECH™ oral technology, optimizing absorption for GLP-1 and other high-demand drugs.

Content Broadcast on: BNN Bloomberg, CNBC, Bloomberg, FOX Business News, BIZTV, Reuters, The Globe and Mail, YouTube and more!